[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-fibrosisnash\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-fibrosisnash":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100580887","stimulating-fat-tissue-storage-with-niacin-to-reduce-fat-accumulation-in-the-liver-100580887",false,"NCT06843148","Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.","Stimulating Adipose Tissue Fatty Acid Disposal With Low-dose, Postprandial, Intermittent Niacin for the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD).","AGL13","Inclusion Criteria:\n\n* aged 20 to 80 years;\n* diagnosed with MASLD, defined as the presence of liver steatosis + abdominal obesity (as defined by the International Diabetes Federation country\u002Fethnic group-specific criteria;\n\nExclusion Criteria:\n\n1\\) Presence of advanced fibrosis using any of the following criteria 1.1 (i.e., ≥ F3 based on liver stiffness \\> 10kPa) using vibration-controlled transient elastography (FibroScan), 1.2 (Index for Liver Fibrosis \\> 2.67) using Fibrosis-4 (FIB-4) which is a calculated score based on age and a combination of lab tests (aspartate aminotransferase \\[AST\\], alanine aminotransferase \\[ALT\\], and platelet count), 1.3 serum ALT \\> 3 times the normal upper limit, 1.4 or signs of portal hypertension. 2) Other hepatic disease. 4) Overt cardiovascular or renal disease, cancer (other than non-melanoma skin cancer), or other uncontrolled medical conditions.\n\n5\\) Any contraindication to MRI. 6) Previous intolerance or allergy to nicotinic acid. 7) Having participated to a research study with exposure to radiation in the last two years before the start of the study.\n\n8\\) Being allergic to eggs 9) Smoking (\\>1 cigarette\u002Fday) and\u002For consumption of \\>2 alcoholic beverages per day.\n\n10\\) Women who are pregnant or breastfeeding.","ALL","20 Years","80 Years",{"count":21,"type":22},36,"ESTIMATED","INTERVENTIONAL",[25],"NA","Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation\u002F fibrosis. MASLD results from fat being disproportionately deposited in the liver.\n\nThe goal of this mechanistic study is to investigate metabolic response in patients aged 20 to 80 years with non-alcoholic fatty liver disease, after niacin (vitamin B3) treatment.\n\nThe main questions it aims to answer are:\n\n* Does Niacin lower the fat deposition in the liver?\n* Does Niacin raise White Adipose Tissue storage of dietary fatty acids?\n\nResearchers will compare Niacin to a placebo (a look-alike substance that contains no drug) to compare the metabolic response.\n\nDuration of study per participant: Up to 28 weeks",[28,29,30],"Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)","Liver Fibrosis\u002FNASH","Non-Alcoholic Steato-Hepatitis (NASH)",[32,33,34,35],"Fatty liver","Niacin","vitamin B3","nicotinic acid","RECRUITING","2026-06-30",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2026-06-22",{"date":44,"type":22},"2030-07",{"name":46,"class":47},"Université de Sherbrooke","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":48},"100628889","exercise-for-an-aging-liver-exaliver-100628889","NCT07467512","Exercise for an Aging Liver (EXALIVER)","Evaluation of the Impact of Physical Exercise on Metabolic Dysfunction-associated Steatotic Liver Disease in the Elderly","EXALIVER","Inclusion Criteria:\n\n* Middle-aged adults (40 to 60 years old) and older adults (aged 70 years or older)\n* People diagnosed with Metabolic Disfunction-Associated Steatotic Liver Disease (MASLD); defined as the presence of hepatic steatosis (≥5% fat content) in conjunction with at least one cardiometabolic risk factor (overweight or obesity, dysglycaemia or Type II diabetes, elevated plasma triglycerides, reduced HDL-cholesterol or high blood preassure) with no other discernable cause.\n* People diagnosed with at-risk Metabolic Disfunction-Associated SteatoHepatitis (MASH) according to the following criteria: I) a positive liver biopsy (NAS score ≥ 4 points (with at least one point in each of the components of the score: steatosis, lobular inflammation and ballooning, AND significant (F2) or advanced (F3) fibrosis), or II) a FAST score \\>0.65.\n\nExclusion Criteria:\n\n* Descompensated cirrhosis or end-stage liver disease.\n* Other causes of liver disease, such as alcohol abuse or drug-induced, virus-related, or hereditary disease.\n* History of a major adverse cardiovascular event, clinically significant kidney, endocrine, or neurological disease, bariatric surgery, HIV\u002FAIDS, known inflammatory and\u002For rheumatologic disease, cancer, or other medical condition in which exercise is absolute contraindicated.\n* Recent or planned major surgery, as well as anticancer therapies.\n* Participating in a weight loss, a weight-management program or a supervised exercise program (more than 30 minutes three times per week, or 45 minutes twice a week, moderate\u002Fvigorous intensity).\n* Body weight instability. Participants must have maintained the body weight registered at screening visit (tolerance: 5%) for more than 3 months.\n* Regular use of medication or compounds that may affect study outcomes based on research staff criteria.\n* Pregnancy and lactation or planned pregnancy (within the study period).\n* Frequent travel over time zones during the study period.\n* Fear of needles and claustrophobia to magnetic resonance imaging (MRI).\n* Low physical function (ie, ambulation dependency)\n* Being unable to understand and to accept the instructions or the study objectives and protocol.","40 Years",{"count":59,"type":22},40,[25],"The goal of this clinical trial is to learn how physical exercise affects liver health in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) or at-risk metabolic dysfunction-associated steatohepatitis (MASH); comparing responses between middle-aged adults (40-60 years old) and older adults (70 years and older) of any sex, as well as between participants with low-risk MASLD and high-risk MASH. The main question it aims to answer is:\n\nCould an exercise program reduce liver fat, inflammation and fibrosis, regardless of age and disease severity?\n\nResearchers will compare 4 different groups:\n\nA) older adults with at risk MASH who will exercise B) middle-aged people with at risk MASH who will exercise C) middle-aged people with low-risk MASLD who will exercise D) middle-aged people with low-risk MASLD who will not exercise, receiving usual care.\n\nParticipants in the exercise groups will take part in a supervised 12-week exercise program that includes both strength and aerobic training, completed twice a week.\n\nAll participants, including those receiving usual care, will have health asssessments before and after the 12-week period to measure changes in liver health.",[63,64,29],"MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","MASH - Metabolic Dysfunction-Associated Steatohepatitis","NOT_YET_RECRUITING","2026-03-09",{"date":68,"type":40},"2026-03-12",{"date":70,"type":22},"2026-03",{"date":72,"type":22},"2027-10",{"name":74,"class":75},"Consorcio Centro de Investigación Biomédica en Red (CIBER)","OTHER_GOV"]